TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29228998

Group type: EXPERIMENTAL
Intervention: Nutritional Perception Screening Questionnaire-9 (NPSQ9)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Personalised nutritional advice based on NPSQ9 scores
Number of subjects: 2369
Study: 29229089

Group type: EXPERIMENTAL
Intervention: Annual assessments of endothelial function by flow-mediated dilatation (FMD)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 6-min walking distance
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Progressive airway obstruction
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Annual decline in FEV1
Number of subjects: 76
Study: 29229100

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 67
Study: 29229365

Group type: EXPERIMENTAL
Intervention: Autologous bone-derived mesenchymal stem cells (H-MSV) seeded on a cross-linked serum scaffold (BioMax)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Contralateral control area of spongy alveolar bone without treatment
Number of subjects: 9
Study: 29229591

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention delivered entirely through an online social network
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional clinic-based lifestyle intervention
Number of subjects: 0
Study: 29229594

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) and nivolumab (Nivo) combination treatment
Number of subjects: 62
Study: 29230307

Group type: EXPERIMENTAL
Intervention: WHO PST programme delivered by family volunteers
Number of subjects: 540
Study: 29230323

Group type: EXPERIMENTAL
Intervention: n-3 PUFA treatment
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 29230539

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) at a dose of 0.4 mg/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 41
Study: 29232153

Group type: COMPARATOR
Intervention: 0 ppb ozone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 70 ppb ozone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 120 ppb ozone
Number of subjects: 87
Study: 29232322

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 119

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 119
Study: 29233022

Group type: EXPERIMENTAL
Intervention: Transcatheter implantation (TAVI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 36
Study: 29233119

Group type: EXPERIMENTAL
Intervention: IBD-AD (active state of disease)
Number of subjects: 47

Group type: COMPARATOR
Intervention: IBD-RE (remission-group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: HC (healthy controls)
Number of subjects: 47
Study: 29233163

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous bone marrow mesenchymal stem cells (BM-MSCs)
Number of subjects: 13
Study: 29233751

Group type: EXPERIMENTAL
Intervention: Sera from children with PANDAS
Number of subjects: 5

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Treatment with intravenous immunoglobulin
Number of subjects: 5
Study: 29233792

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation (2 × 600mg, twice daily, for 30 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29233821

Group type: EXPERIMENTAL
Intervention: Duvelisib (IPI-145)
Number of subjects: 35
Study: 29234302

Group type: EXPERIMENTAL
Intervention: Home-based virtual reality training
Number of subjects: 12
Study: 29234503

Group type: EXPERIMENTAL
Intervention: Enteral cholecalciferol loading dose (10,000 IU/kg, maximum of 400,000 IU)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 67
Study: 29234571

Group type: EXPERIMENTAL
Intervention: IL-37 serum levels measured in stroke patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IL-37 urine levels measured in stroke patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trends in serum and urine IL-37 levels
Number of subjects: 12
Study: 29234955

Group type: EXPERIMENTAL
Intervention: End of treatment measures of mental health status, work ability, generalized self-efficacy, and expectations of future work ability.
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Expectancy of future work ability improvement or positivity from before to the end of treatment.
Number of subjects: 106
Study: 29235062

Group type: EXPERIMENTAL
Intervention: First vismodegib course (FVC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Second vismodegib course (SVC)
Number of subjects: 6
Study: 29235365

Group type: EXPERIMENTAL
Intervention: Triple combination therapy with 20 mg azilsartan, 5 mg amlodipine, and 12.5 mg hydrochlorothiazide (AZL/AML/HCTZ)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Triple combination therapy with AZL/AML/HCTZ
Number of subjects: 341

Group type: COMPARATOR
Intervention: AZL/AML therapy
Number of subjects: 341
Study: 29236734

Group type: EXPERIMENTAL
Intervention: Freeze-dried Lactobacillus plantarum 299v (Lp299v), 1010 cfu
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (meal without Lp299v)
Number of subjects: 42
Study: 29236912

Group type: EXPERIMENTAL
Intervention: Underwater treadmill test
Number of subjects: 40

Group type: COMPARATOR
Intervention: Land treadmill test
Number of subjects: 40
Study: 29237053

Group type: EXPERIMENTAL
Intervention: Previous-wave alcohol use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eleventh grade social jetlag
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eleventh grade chronotype and social jetlag
Number of subjects: 0
Study: 29237284

Group type: EXPERIMENTAL
Intervention: Physical activity during migraine attacks
Number of subjects: 132
Study: 29237444

Group type: EXPERIMENTAL
Intervention: INDI collaborative care model implementation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparable areas)
Number of subjects: 0
Study: 29237583

Group type: EXPERIMENTAL
Intervention: Standard referral (counseling and a referral note)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Standard referral plus SMS text message (short message service, SMS)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: SMS text message
Number of subjects: 1200

Group type: COMPARATOR
Intervention: One-time financial incentive (approximately US $4)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Primary prevention messaging intervention
Number of subjects: 1200
Study: 29237618

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 0
Study: 29237655

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) with Confirm Rx implanted subcutaneously after local anaesthesia, monitoring for non-sustained ventricular tachycardia (NSVT) and atrial fibrillation (AF) over 18 months.
Number of subjects: 30
Study: 29237801

Group type: EXPERIMENTAL
Intervention: Postoperative LOC eating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presurgical LOC eating
Number of subjects: 0

Group type: COMPARATOR
Intervention: LOC eating at baseline
Number of subjects: 0
Study: 29238851

Group type: EXPERIMENTAL
Intervention: Mocetinostat 90 mg TIW + gemcitabine 1000 mg/m²
Number of subjects: 48
Study: 29239002

Group type: EXPERIMENTAL
Intervention: 40 mg osimertinib once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 80 mg osimertinib once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 31
Study: 29239129

Group type: EXPERIMENTAL
Intervention: GDM+
Number of subjects: 86

Group type: COMPARATOR
Intervention: GDM-
Number of subjects: 86
Study: 29239951

Group type: EXPERIMENTAL
Intervention: Noninvasive hemoglobin measurements (SpHb)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Blood gas hemoglobin measurements
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Noninvasive hemoglobin measurement (SpHb)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Acute Physiology and Chronic Health Evaluation II score
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure
Number of subjects: 146
Study: 29239953

Group type: EXPERIMENTAL
Intervention: TXA (1 g intravenously)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 70
Study: 29240542

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal
Number of subjects: 51
Study: 29241084

Group type: EXPERIMENTAL
Intervention: Capecitabine 825 mg/m² combined with sorafenib and radiotherapy (45 Gy in 25 fractions over 5 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Phase I study to establish maximum tolerated dose
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Phase II study assessing efficacy and safety
Number of subjects: 54
Study: 29241485

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDL-C) levels
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels
Number of subjects: 1779
Study: 29241640

Group type: EXPERIMENTAL
Intervention: Anti-CCP positive
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: RF positive
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: Anti-CCP positive and erosions
Number of subjects: 1309
Study: 29241979

Group type: EXPERIMENTAL
Intervention: Acalabrutinib (100 mg twice per day)
Number of subjects: 124
Study: 29242085

Group type: EXPERIMENTAL
Intervention: Self-assessment strategy using multilevel pregnancy test (MLPT) and symptom evaluation
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Self-assessment strategy using MLPT
Number of subjects: 343
Study: 29242184

Group type: EXPERIMENTAL
Intervention: ST-segment-elevation myocardial infarction (STEMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: non-ST-segment elevation myocardial infarction (non-STEMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: non-STEMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 0
Study: 29242240

Group type: EXPERIMENTAL
Intervention: T2 mapping performed at 2 days and 6 months post-STEMI
Number of subjects: 283
Study: 29242352

Group type: EXPERIMENTAL
Intervention: Modified EFFECT score including age, systolic blood pressure, blood urea nitrogen, sodium, cerebrovascular disease, chronic obstructive pulmonary disease, and hemoglobin.
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Modified EFFECT score
Number of subjects: 1852
Study: 29242398

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29242404

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29242845

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (dietary instructions)
Number of subjects: 50
Study: 29242852

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative mMUD BMT with high-dose posttransplantation cyclophosphamide (PTCy)
Number of subjects: 20
Study: 29243075

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin q.d. for 8 weeks
Number of subjects: 40
Study: 29243168

Group type: EXPERIMENTAL
Intervention: Physical activity engagement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Symptoms of metastatic prostate cancer and treatment side effects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Generic barriers to physical activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Referral to a cancer exercise specialist
Number of subjects: 20
Study: 29243222

Group type: EXPERIMENTAL
Intervention: Durvalumab (anti-PD-L1 monoclonal antibody)
Number of subjects: 0
Study: 29243287

Group type: EXPERIMENTAL
Intervention: Dabrafenib 300 mg BID
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dabrafenib 300 mg
Number of subjects: 43
Study: 29243344

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Anxiety/Depression
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: PTSS
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sleep Disturbance
Number of subjects: 118
Study: 29243546

Group type: EXPERIMENTAL
Intervention: Cancer therapy
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Sedatives
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Long-term prevention medications
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Heart medication/anti-hypertensives
Number of subjects: 720
Study: 29243796

Group type: EXPERIMENTAL
Intervention: Myo-inositol/D-chiro-inositol ratio in follicular fluid
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Myo-inositol pre-treatment in women undergoing IVF
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lower D-chiro-inositol content in follicular fluid
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Myo-inositol/D-chiro-inositol ratio
Number of subjects: 19
Study: 29244129

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based regimen
Number of subjects: 20
Study: 29244126

Group type: EXPERIMENTAL
Intervention: PLHIV
Number of subjects: 456

Group type: COMPARATOR
Intervention: HUCs
Number of subjects: 456
Study: 29244149

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) 162 mg each week for ⩾24 weeks as monotherapy
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) 162 mg each week for ⩾24 weeks in combination with csDMARDs
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Subcutaneous tocilizumab (TCZ-SC)
Number of subjects: 1804
Study: 29244957

Group type: EXPERIMENTAL
Intervention: ENPP1 mutation treatment (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 29245152

Group type: EXPERIMENTAL
Intervention: Pelvic radiation exposure during percutaneous coronary procedures
Number of subjects: 138
Study: 29245310

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg qd) plus Irinotecan (340 mg/m or 125 mg/m depending on use of enzyme-inducing antiepileptic drugs) for 6 cycles, followed by maintenance with apatinib.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Apatinib plus Irinotecan
Number of subjects: 10
Study: 29246128

Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D concentration during pregnancy (≥ 80 nmol/L)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D concentration in umbilical cord blood (UCB)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Maternal 25(OH)D concentration
Number of subjects: 723

Group type: COMPARATOR
Intervention: Oral glucose tolerance test results
Number of subjects: 723
Study: 29246134

Group type: EXPERIMENTAL
Intervention: Mobile-bearing UKA with anterior notch
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mobile-bearing UKA with larger anterior notch
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mobile-bearing UKA
Number of subjects: 24
Study: 29246150

Group type: EXPERIMENTAL
Intervention: Low-dose lymphocyte immunotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study: 29246151

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 2703

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (primary CVD prevention)
Number of subjects: 2703

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (secondary CVD prevention)
Number of subjects: 2703

Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus
Number of subjects: 2703
Study: 29246159

Group type: EXPERIMENTAL
Intervention: MIB-1 proliferation index (Ki-67) ≥10%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ≥4 mitoses per 10 high power fields
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tumor size larger than 10 cm
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 78
Study: 29246331

Group type: EXPERIMENTAL
Intervention: Class IV obesity
Number of subjects: 2244

Group type: COMPARATOR
Intervention: Class III obesity
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Male children
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Baseline class IV obesity
Number of subjects: 2244

Group type: COMPARATOR
Intervention: Baseline class III obesity
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Changes in degree of obesity
Number of subjects: 2244
Study: 29246428

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with BAV
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with type 0 BAV
Number of subjects: 157
Study: 29246432

Group type: EXPERIMENTAL
Intervention: WTC Health Registry (WTCHR) participants
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-WTCHR participants
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Home dust exposure
Number of subjects: 110
Study: 29246803

Group type: EXPERIMENTAL
Intervention: Venetoclax (starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 mg per day; accelerated dosing schedule for rapidly progressing disease to 400 mg per day by week 3)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Venetoclax (in the main cohort of 43 patients)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Venetoclax (in the expansion cohort of 48 patients)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 127
Study: 29246886

Group type: EXPERIMENTAL
Intervention: Travel to India
Number of subjects: 149

Group type: COMPARATOR
Intervention: No colonization with ESBL-producing bacteria
Number of subjects: 149
Study: 29246900

Group type: EXPERIMENTAL
Intervention: Gene therapy with AMT-060 (AAV5 vector with liver-specific promoter)
Number of subjects: 10
Study: 29246909

Group type: EXPERIMENTAL
Intervention: Ultimaster drug-eluting stent
Number of subjects: 60
Study: 29246916

Group type: EXPERIMENTAL
Intervention: Aspirin and ticagrelor without stenting for ≤1 month
Number of subjects: 53
Study: 29246917

Group type: EXPERIMENTAL
Intervention: Pressure microcatheter over pressure wire
Number of subjects: 169

Group type: COMPARATOR
Intervention: Pressure wire alone
Number of subjects: 169
Study: 29246923

Group type: EXPERIMENTAL
Intervention: Cytoreductive drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic drugs
Number of subjects: 0
Study: 29246938

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29247021

Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523) at a recommended phase II dose (RP2D) of 600 mg twice daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523)
Number of subjects: 135
Study: 29247063

Group type: EXPERIMENTAL
Intervention: Topical and systemic tracer of vascular endothelial growth factor A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29247084

Group type: EXPERIMENTAL
Intervention: High-resolution susceptibility weighted MRI
Number of subjects: 145

Group type: COMPARATOR
Intervention: DaTSCAN
Number of subjects: 145

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 145
Study: 29247101

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered CBT supplemented with group exposure sessions
Number of subjects: 30
Study: 29247143

Group type: EXPERIMENTAL
Intervention: Cognitive impairment before ICH (24.7% prevalence, n=41)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: CAA defined using magnetic resonance imaging markers
Number of subjects: 166
Study: 29247524

Group type: EXPERIMENTAL
Intervention: Clinical events (time to first occurrence of any event from the composite cardiovascular endpoint of MI, unstable angina with urgent revascularization, stroke, or death from any cause)
Number of subjects: 9225

Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization (hospitalization duration and procedures)
Number of subjects: 9225

Group type: EXPERIMENTAL
Intervention: Quality of life (self-reported health)
Number of subjects: 9225
Study: 29247830

Group type: EXPERIMENTAL
Intervention: AUY922 (70 mg/m weekly intravenous)
Number of subjects: 153
Study: 29247912

Group type: EXPERIMENTAL
Intervention: Presence of small pericardial effusion (SPE)
Number of subjects: 154

Group type: COMPARATOR
Intervention: No small pericardial effusion (SPE)
Number of subjects: 154
Study: 29247976

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 15
Study: 29248236

Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) with intramuscular testosterone cipionate 400 mg every 28 days until progression and continued luteinising hormone-releasing hormone agonist therapy.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rechallenge with oral enzalutamide 160 mg daily after progression on BAT.
Number of subjects: 30
Study: 29248241

Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control
Number of subjects: 198
Study: 29248263

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 2
Study: 29248319

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin (GC) plus Ipilimumab
Number of subjects: 36
Study: 29248621

Group type: EXPERIMENTAL
Intervention: Childhood asthma
Number of subjects: 4915

Group type: EXPERIMENTAL
Intervention: ACO (Asthma-COPD Overlap)
Number of subjects: 4915

Group type: EXPERIMENTAL
Intervention: Childhood pneumonia
Number of subjects: 4915

Group type: COMPARATOR
Intervention: No early-life respiratory diseases (Control)
Number of subjects: 4915
Study: 29248659

Group type: EXPERIMENTAL
Intervention: Ferumoxytol-Enhanced Magnetic Resonance Angiography
Number of subjects: 0
Study: 29248669

Group type: EXPERIMENTAL
Intervention: Haemopoietic stem-cell transplantation (HSCT) after myeloablation
Number of subjects: 23
Study: 29248894

Group type: EXPERIMENTAL
Intervention: Standardised frankincense extract (SFE)
Number of subjects: 38
Study: 29249180

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine
Number of subjects: 378